Efinopegdutide vs HM15211

Head-to-head comparison of Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) and HM15211 (HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyEfinopegdutideHM15211
CategoryWeight ManagementWeight Management
Full NameEfinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonistHM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist
Molecular WeightN/AN/A
Half-LifeApproximately 1 weekApproximately 1 week
Amino AcidsN/AN/A
Typical DoseTrial-dependent; weekly SC dosingInvestigational; no established human dose
RouteSubcutaneousSubcutaneous
Purity≥98%≥98%
Studies Count1412
Research StatusClinicalClinical

Efinopegdutide Benefits

  • reduced body weight
  • improved insulin sensitivity
  • reduced liver fat
  • greater satiety

HM15211 Benefits

  • appetite suppression
  • greater fat oxidation
  • weight loss
  • improved metabolic markers

Efinopegdutide Dosing

once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials

HM15211 Dosing

once-weekly subcutaneous injection|titration to effect|maintenance at tolerated dose

Efinopegdutide Side Effects

  • nausea
  • decreased appetite
  • fatigue

HM15211 Side Effects

  • nausea
  • vomiting
  • reduced appetite

Research Overview

Efinopegdutide

Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.

HM15211

Research has shown potent weight-reducing and metabolic effects in preclinical and translational studies. The compound is being developed as a next-generation incretin-based therapy.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Efinopegdutide stacks with:

metforminorlistat

HM15211 stacks with:

metformintopiramate
glp1glucagondual-agonistobesitynashgiptriagonist